AK
Aktis Oncology, Inc.
AKTS · NASDAQ
$24.06 -5.91% (-$1.51)
1M -2.87%
Market Cap $1.28B
P/E Ratio -
Div. Yield -
ROE 35.78%
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 197.77x
EV/FFO N/A
P/E N/A
Growth
-
N/A FCF growth N/A
EPS growth N/A
Book val. growth N/A
Profitability
20 /100
Weak Op. margin 1,149.52%
Gross margin 100.00%
FCF margin 1,134.54%
Quality
0 /100
Poor ROA 24.06%
ROIC 31.79%
Asset turnover 0.02x
Debt
100 /100
Low Current ratio 7.37x
Net debt/EBITDA N/A
Debt/Equity N/A
Stability
47 /100
Moderate Profitable years 0
Beta 0.45x
EPS volatility 36.42%
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o AKTS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Matthew Roden
Employees
79
Headquarters
Boston
Prihajajoči dogodki
12 NOV.
Earnings
Upcoming earnings report